Study #2014-0431
Allogeneic Transplantation Using Venetoclax, Timed Sequential Busulfan, Cladribine, and Fludarabine Conditioning in Patients with AML and MDS
MD Anderson Study Status
Enrolling
Treatment Agent
Busulfan, Cladribine, Fludarabine Phosphate, Venetoclax
Description
This randomized phase II trial studies how well venetoclax and sequential busulfan, cladribine, and fludarabine phosphate before donor stem cell transplant work in treating patients with acute myelogenous leukemia or myelodysplastic syndrome. Giving chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
Information and next steps
Disease:
Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndrome
Study phase:
II
Physician name:
Uday Popat
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-877-632-6789
Help us #endcancer
Give Now
Donate Blood
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.